Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898850 | 1.00 | GABRR1 (0.42) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL1601477 | 1.00 | GABRR1 (0.42) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL8436474 | 0.79 | GABRR1 (0.42) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL7193017 | 0.79 | GABRR1 (0.42) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL27431345 | 0.79 | GABRR1 (0.42) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL8779426 | 0.77 | PMP22 (0.34) | GABRR1PMP22NOS2 | |
| SCHEMBL8749887 | 0.77 | PMP22 (0.34) | GABRR1PMP22NOS2 | |
| SCHEMBL7337250 | 0.77 | GABRR1 (0.41) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL14113248 | 0.77 | GABRR1 (0.46) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL4908056 | 0.77 | GABRR1 (0.46) | GABRR1CYP1A2FOLH1NAALAD2ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1697344-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7834043-B2 | Prevent reproduct of aids virus | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558657-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | GABRR1 2997/4885CYP1A2 3513/4885FOLH1 189/4885 |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | GABRR1 2254/4885CYP1A2 2459/4885FOLH1 252/4885 |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | GABRR1 2254/4885CYP1A2 2459/4885FOLH1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.